Humoral and cellular responses after COVID-19 vaccination in anti-CD20-treated lymphoma patients.

Liebers, Nora; Speer, Claudius; Benning, Louise; Bruch, Peter-Martin; Kraemer, Isabelle; Meissner, Julia; Schnitzler, Paul; Kräusslich, Hans-Georg; Dreger, Peter; Mueller-Tidow, Carsten; Poschke, Isabel; Dietrich, Sascha

Liebers, Nora; Speer, Claudius; Benning, Louise; Bruch, Peter-Martin; Kraemer, Isabelle; Meissner, Julia; Schnitzler, Paul; Kräusslich, Hans-Georg; Dreger, Peter; Mueller-Tidow, Carsten; Poschke, Isabel; Dietrich, Sascha.

Liebers N; Department of Medicine V, Heidelberg University Hospital, Heidelberg, Germany.
Speer C; National Center for Tumor Diseases Heidelberg, Heidelberg, Germany.
Benning L; Department of Nephrology, Heidelberg University Hospital, Heidelberg, Germany.
Bruch PM; Department of Nephrology, Heidelberg University Hospital, Heidelberg, Germany.
Kraemer I; Department of Medicine V, Heidelberg University Hospital, Heidelberg, Germany.
Meissner J; Department of Medicine V, Heidelberg University Hospital, Heidelberg, Germany.
Schnitzler P; Department of Medicine V, Heidelberg University Hospital, Heidelberg, Germany.
Kräusslich HG; Department of Infectious Diseases, Virology, Heidelberg University Hospital, Heidelberg, Germany.
Dreger P; Department of Infectious Diseases, Virology, Heidelberg University Hospital, Heidelberg, Germany.
Mueller-Tidow C; Department of Medicine V, Heidelberg University Hospital, Heidelberg, Germany.
Poschke I; Department of Medicine V, Heidelberg University Hospital, Heidelberg, Germany.
Dietrich S; National Center for Tumor Diseases Heidelberg, Heidelberg, Germany.

Blood ; 139(1): 142-147, 2022 01 06.

Article in English | MEDLINE | ID: covidwho-1477252

Subject(s)

COVID-19 Vaccines/administration & dosage; COVID-19/immunology; COVID-19/prevention & control; Lymphoma/immunology; Lymphoma/therapy; SARS-CoV-2/immunology; Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized/adverse effects; Antibodies, Monoclonal, Humanized/therapeutic use; Antibodies, Neutralizing/biosynthesis; Antibodies, Viral/biosynthesis; Antigens, CD20/immunology; Antineoplastic Agents, Immunological/adverse effects; Antineoplastic Agents, Immunological/therapeutic use; Female; Humans; Immunity, Cellular; Immunocompromised Host; Male; Middle Aged; Multivariate Analysis; Rituximab/adverse effects; Rituximab/therapeutic use; Seroconversion; Young Adult

Fulltext

XML

PubMed Links

Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: COVID-19 Vaccines / SARS-CoV-2 / COVID-19 / Lymphoma Topics: Vaccines Limits: Adult / Aged / Female / Humans / Male / Middle aged / Young adult Language: English Journal: Blood Year: 2022 Document Type: Article Affiliation country: Blood.2021013445

Similar

MEDLINE

LILACS

LIS

Fulltext

XML

PubMed Links

Search on Google